VANTAS(R) to be Only Once-Yearly Implant for Prostate Cancer in U.S. Market
Indevus Reaffirms Commitment to Prostate Cancer Patients
LEXINGTON, Mass., Dec. 20 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today commented on the announcement by Bayer Healthcare that they would discontinue marketing their product Viadur(R) (leuprolide acetate implant), which is indicated for the palliative treatment of advanced prostate cancer. As a result of this announcement, Indevus' product VANTAS(R) (histrelin implant) will be the only 12-month implant for the palliative treatment of advanced prostate cancer. Indevus remains committed to providing patients and physicians effective options for the treatment of advanced prostate cancer.
"Indevus is firmly committed to providing continuity of care for current Viadur patients," stated Kurt W. Lewis, senior vice president, sales and marketing of Indevus. "We will ensure that physicians have ready access to VANTAS, therefore enabling a smooth transition for those patients who desire a once-yearly therapy for the treatment of advanced prostate cancer."
"VANTAS is appropriate for patients who are candidates for long-term LHRH therapy," stated James E. Shipley, M.D., senior vice president clinical development and medical affairs of Indevus. "VANTAS provides the flexibility that only the technology of our once-yearly Hydron Implant can offer, resulting in improved patient compliance and physician efficiency."
More information regarding VANTAS is available at http://www.vantasimplant.com or by calling 888-282-5372.
VANTAS(R) is a soft and flexible 12-month hydrogel impla
|SOURCE Indevus Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved